CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Chris Learn, PhD, MBA, PMP
Advertisement
Chris Learn, Ph.D., M.B.A., P.M.P., Senior Vice President, Head, Cell and Gene Therapy and Early Phase at Parexel, has helped guide more than 20 gene therapy programs through development.
Articles by Chris Learn, PhD, MBA, PMP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: GSK Acquires Trispecific T Cell-Engager from Chimagen, Sanofi & Cheplapharm Form Strategic Partnership
2
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
3
Novo Nordisk Rebranding to'Novo'
4
Why Some Diabetes Patients Fail to Respond to Incretin Therapies: Q&A with Dr. Elena Christofides
5